Jeil Pharmaceutical (271980) Fundamentals 2026 — P/E 5.0x, Revenue Analysis | SniperIQ
Jeil Pharmaceutical (271980) is a KR-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₩144.0B, trading at ₩9790.00 on the KSC. This SniperIQ fundamentals page covers Jeil Pharmaceutical's valuation (P/E 5.0x, P/B 0.7x), profitability (net margin 3.8%), revenue (₩566.3B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Jeil Pharmaceutical's market cap?
Jeil Pharmaceutical (271980) has a market capitalization of approximately ₩144.0B, trading at ₩9790.00 on the KSC. Market cap moves with the live share price.
What is Jeil Pharmaceutical's P/E ratio?
Jeil Pharmaceutical's trailing twelve-month P/E ratio is 5.0x, with a price-to-book (P/B) of 0.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Jeil Pharmaceutical?
Jeil Pharmaceutical runs a net profit margin of 3.8%, a gross margin of 38.7%, and an operating margin of 2.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Jeil Pharmaceutical generate?
Jeil Pharmaceutical reported revenue of ₩566.3B for fiscal year 2025, with net income of ₩23.4B and earnings per share (EPS) of 1604.77. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Jeil Pharmaceutical pay a dividend?
Jeil Pharmaceutical does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Jeil Pharmaceutical financially healthy?
Jeil Pharmaceutical carries a debt-to-equity ratio of 0.46x and a current ratio of 1.35x, with a market beta of 1.53. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Jeil Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Jeil Pharmaceutical (271980) the key facts are: market cap ₩144.0B, P/E 5.0x, revenue ₩566.3B, 52-week range 9100-19290. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Jeil Pharmaceutical's full fundamentals live
Get Jeil Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.